LCOR Inhibitors
LCOR Inhibitors, in this context, are chemicals that indirectly target LCOR by influencing nuclear receptor signaling or epigenetic mechanisms of gene regulation. LCOR functions as a corepressor for various nuclear receptors, and its activity is closely linked to the transcriptional regulation mediated by these receptors. Tamoxifen and Fulvestrant, by modulating estrogen receptor activity, may affect the corepressor functions of LCOR in estrogen receptor-related pathways. Trichostatin A and Vorinostat, as histone deacetylase inhibitors, can alter chromatin structure and gene expression patterns, potentially impacting the transcriptional repression activities of LCOR.
Mifepristone, a glucocorticoid and progesterone receptor antagonist, and androgen receptor antagonists like Flutamide, Enzalutamide, and Bicalutamide might influence LCOR's interaction with these hormone-related pathways. 5-Azacytidine, a DNA methyltransferase inhibitor, could affect the epigenetic regulation of genes in which LCOR is involved. PI3K inhibitors such as LY294002 can modulate signaling pathways that might have downstream effects on LCOR's activity. Lastly, ATRA (All-trans Retinoic Acid) can modulate retinoic acid receptor activity, potentially influencing the corepressor function of LCOR in retinoic acid-mediated gene regulation.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $272.00 | 18 | |
A selective estrogen receptor modulator (SERM), potentially affecting LCOR's corepressor activity on estrogen receptors. | ||||||
ICI 182,780 | 129453-61-8 | sc-203435 sc-203435A | 1 mg 10 mg | $83.00 $187.00 | 34 | |
An estrogen receptor antagonist, might influence LCOR's interaction with estrogen-related pathways. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
A histone deacetylase inhibitor, could impact chromatin structure and gene expression patterns involving LCOR. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Another histone deacetylase inhibitor, potentially affecting LCOR-mediated transcriptional repression. | ||||||
Mifepristone | 84371-65-3 | sc-203134 | 100 mg | $61.00 | 17 | |
A glucocorticoid and progesterone receptor antagonist, may indirectly affect LCOR's corepressor functions. | ||||||
Flutamide | 13311-84-7 | sc-204757 sc-204757A sc-204757D sc-204757B sc-204757C | 1 g 5 g 25 g 500 g 1 kg | $47.00 $156.00 $171.00 $525.00 $941.00 | 4 | |
Inhibits androgen receptor signaling, potentially impacting LCOR's role in androgen receptor-mediated pathways. | ||||||
MDV3100 | 915087-33-1 | sc-364354 sc-364354A | 5 mg 50 mg | $245.00 $1051.00 | 7 | |
An androgen receptor antagonist, could modulate LCOR's involvement in androgen receptor pathways. | ||||||
Bicalutamide | 90357-06-5 | sc-202976 sc-202976A | 100 mg 500 mg | $42.00 $146.00 | 27 | |
Another androgen receptor antagonist, potentially affecting LCOR's role in hormone signaling pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Inhibits the PI3K signaling pathway, potentially influencing signaling pathways involving LCOR. | ||||||